Technology ID
TAB-3757
Compounds and Methods for Treating Brain Injury
E-Numbers
E-138-2017-0
Lead Inventor
Korinek, William (Astrocyte Pharmaceuticals, Inc)
Co-Inventors
Jacobson, Kenneth (NIDDK)
Lechleiter, James (University of Texas Health Science Center)
Liston, Theodore (Astrocyte Pharmaceuticals, Inc)
Applications
Therapeutics
Research Materials
Therapeutic Areas
Neurology
Lead IC
NIDDK
ICs
NIDDK
This technology includes MRS4322, which is an A3 agonist that is currently being evaluated for treatment of traumatic brain injury. Although its affinity in the receptor is in the micromolar range, it enters the brain in sufficient concentration to activate a protective CNS receptor, A3 adenosine receptor. Potential applications of such A3 agonists could also include neurodegenerative conditions.
Commercial Applications
Treatment of traumatic brain injury and neurodegenerative conditions.
Competitive Advantages
This compound produced fully agonizes the human A3 adenosine receptor with µmolar affinity with moderate selectivity vs. other adenosine receptors and displays the appropriate physicochemical properties for effective agonism and bioavailability in vivo.
Licensing Contact: